DelMar Pharmaceuticals Presents Planned Clinical Trial Protocol for Non-Small Cell Lung Cancer Therapy

Lung Cancer, News

DelMar Pharmaceuticals, Inc. a biopharmaceutical company that develops and commercializes new treatments for cancer, recently presented an outline of its planned clinical trial protocol for its lead drug candidate VAL-083 (dianhydrogalactitol) for ... Read more

August 25, 2015August 25, 2015

DelMar Pharmaceuticals Will Present VAL-083 Lung Cancer Clinical Strategy

Lung Cancer, News

DelMar Pharmaceuticals, Inc., a biopharmaceutical firm focused on the advancement and commercialization of novel cancer therapies, recently announced it has been invited to present a clinical strategy overview concerning VAL-083 (dianhydrogalactitol) and its potential as a treatment for patients ... Read more